Business
PTC Buys a Fabry Disease Gene Therapy From Bankrupt Sangamo for Up to $211M
The one-time gene therapy ST-920 is heading toward an FDA filing; PTC picked it up at auction after gene-medicine pioneer Sangamo filed for bankruptcy.